Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04642820 · ClinicalTrials.gov registry record · Early Phase 1
Drugs Brain and Behavior (DDP)
A Early Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 138
- Enrollment target
NCT04642820: Completed Early Phase 1 study, sponsored by University of Chicago.
NCT04642820 is a Early Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 138 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (160% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04642820, a Early Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 138 participants
- Enrollment target
Study Summary
In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.
Primary Outcome
Participants will complete The Drug Effects Questionnaire during the initial baseline session to determine their subjective stimulant profile. The Dug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: "Feel Drug", "Feel High", "Like Drug", and "Want More". All sub-scales are scored on a visual analogue scale (Scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that s
Interventions
- DRUG Methamphetamine
- DRUG placebo oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2024-06-01 |
| Phase | Early Phase 1 |
What the finished NCT04642820 record still lists
NCT04642820 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (160% higher).
The record links to 0 conditions, and to 2 interventions - of which Methamphetamine is the first listed.
NCT04642820 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04642820 about?
NCT04642820 is a clinical study titled "Drugs Brain and Behavior (DDP)". In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.
What is the current status of trial NCT04642820?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 138 participants. The study started on 2020-11-01. Estimated completion is 2024-06-01.
What interventions are being tested in trial NCT04642820?
The interventions under investigation include: Methamphetamine (DRUG), placebo oral tablet (DRUG).
Who is sponsoring clinical trial NCT04642820?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04642820's enrollment target sits among peer trials
138 122nd of 2000 higher than 1,877 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI